Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, with Portion Executed Via ASR in First Quarter 2024 Reaffirms Previously Provided Outlook for Full-Year 2023 BLOOMFIELD, Conn. , Dec. 10, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today announced that its Board of Directors has approved an aggregate increase of $10 billion in incremental share repurchase authorization, bringing the company's total share repurchase authority to $11.3 billion.

The Cigna Group Announces Significant Increase to Share Repurchase Program of $10 Billion

Humana

U.S. health insurer Cigna has called off its deal to buy Humana , scrapping a deal that could have created a roughly $140 billion giant in the health-insurance industry, the Wall Street Journal reported on Sunday

US health insurer Cigna scraps deal to buy Humana -WSJ

The health-insurance providers couldn't agree on financial terms for a deal that would have created a $140 billion giant.

Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

Apple

Microsoft

iShares MSCI USA Quality Factor ETF

After outperforming for much of the years, shares of solid, steady companies have been stuck in place.

‘Quality Stocks' Are Taking a Break. Cigna and 4 More That Look Interesting.

APA Corporation

Paycom Software

Paycom stock plunged after its guidance missed the mark. Investors gave a thumbs down to a possible Cigna-Humana merger.

Is It Time to Buy the S&P 500's 3 Worst-Performing November Stocks?

Bank of America

Discover

Domino's Pizza

EOG Resources

Microchip Technology

MSCI

Rollins

Charles Schwab

Sirius XM Holdings Inc

SPDR S&P 500 ETF Trust

SS&C Technologies Hlds

Tractor Supply

Texas Instruments

Visa

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF was up 9.13% in November, Vanguard's Dividend Appreciation ETF was up 7.47%, my watchlist beat both with a return of 10.24%. The top 15 dividend growth stocks for December offer an average dividend yield of 1.99% and appear to be about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is rocking a cool 11.76% annualized return, beating VIG by 2.36% and SPY by 1.52%.

My Top 15 High Growth Dividend Stocks For December 2023

Automatic Data Processing

Albemarle

American Homes 4 Rent

Ares Capital

Alexandria Real Estate Equities

Bristol-Myers

British American Tobacco

Caterpillar

Citizens Financial Group

Cincinnati Financial

Cisco Systems

Chevron

Deere & Company

Dollar General

Diamondback Energy

Genuine Parts

Hershey

Johnson & Johnson

JPMorgan Chase & Co

Lennar

Altria

MPLX

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023

Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. NYSE: HUM is reportedly in talks to merge with The Cigna Group NYSE: CI in a stock-and-cash deal.

Mega merger in the works? Humana, Cigna explore big deal

Humana (NYSE:HUM) Inc and its US health insurance peer Cigna (NYSE:CI) Group are discussing a deal to merge, Reuters reported on Friday, citing people familiar with the matter.  The agreement, which could exceed $60 billion in value, would likely create intense antitrust scrutiny, the media outlet reported.

Humana and Cigna Group in merger talks: report

DBV Technologies SA Sponsored ADR

Kintara Therapeutics

MEDNAX

Patterson Companies

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

ConocoPhillips

Hess

Walgreens

Exxon Mobil

Energy was the sole S&P 500 sector to decline this month as the index marched toward its best month since July 2022.

These Stocks Were Left Behind In November's Historic Rally

U.S. health insurers Cigna and Humana are in talks to merge, a potential deal likely to face aggressive scrutiny from the U.S. Justice Department (DOJ) if antitrust history with similarly sized deals is any indication. The deal could exceed $60 billion in value.

Explainer: Why prior mega health insurer deals like the possible Cigna/Humana merger failed

Air Products and Chemicals

Becton, Dickinson and Co.

Dover

Mattel

This month, I've published two pieces about technical analysis — one on Bollinger Bands and another on the Relative Strength Indicator (RSI).

7 Blue-Chip Stocks to Buy for 2024, According to AI

UnitedHealth Group

The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.

Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles

A combination of the two health insurers will be scrutinized by the government, but that doesn't mean it won't have a good argument at court.

Cigna-Humana Merger Is Likely to Face Antitrust Challenge

News of a potential mega-merger between Cigna (CI) and Humana (HUM) made headlines in today's trading session and investors may be wondering if now is a good time to buy stock in these health giants.

Time to Buy Cigna (CI) or Humana's (HUM) Stock on News of a Potential Merger?

Humana and Cigna are reportedly in talks for a potential merger that could reshape the health insurance industry. A deal could be finalized by the end of the year, The Wall Street Journal (WSJ) reported Wednesday (Nov. 29), citing unnamed sources.

Report: Health Insurance Firms Humana and Cigna in Merger Talks

Shares of Cigna Group (CI) and Humana Inc. (HUM) plummeted during intraday trading Wednesday after a report that the huge health insurance companies could merge.

Cigna and Humana Shares Tumble After Report of Possible Merger

News for Cigna Stock (CI)